关于empagliflozin抗心律失常作用的性别差异:EMPA-ICD试验的细分分析
Miyo Nakano1, Yusuke Kondo2, Shinya Fujiki3
1Department of Advanced Cardiorhythm Therapeutics, Chiba University Graduate School of Medicine, Chiba, Japan.
JACC. Asia
|January 22, 2026
概括
在患有2型糖尿病和可植入心脏转换器-除器 (ICD) 的男性中,empagliflozin可以减少心室失常 (VAs). 这种药物在女性中没有显著减少VA,这表明性别特异性的治疗反应.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 在EMPA-ICD试验中,评估了empagliflozin对2型糖尿病 (T2DM) 患者的腹腔失常 (VAs) 的作用,这些患者使用可植入心脏转换器-除器 (ICD).
- 之前的研究结果表明,empagliflozin可以降低VA,但性别特异性疗效尚不清楚.
研究的目的:
- 为了研究empagliflozin抗心律失常作用的性别特异性差异.
- 在EMPA-ICD试验中,根据患者的性别分析empagliflozin在减少VA的疗效.
主要方法:
- 一个前性,随机,双盲,安慰剂控制的研究设计.
- 主要终点:通过ICD在24周内检测到的VA数量的变化 (不持续的VT,持续的VT,VF).
- 在日本31个中心,150名患有ICD的T2DM患者被随机分配给empagliflozin或安慰剂.
主要成果:
- 恩帕格利弗洛辛在男性中显著降低了VA (比率比:0.33,P<0.001).
- 在女性中没有观察到显著的VA减少 (比率比:1.78,P = 0.35).
- 性别和治疗之间的显著相互作用 (P = 0.006) 表明了特定于性别的治疗反应.
结论:
- 在接受ICD治疗的T2DM患者中,empagliflozin的抗失常作用在男性中比女性更为明显.
- 这些发现凸显了对-葡萄糖共运输体2抑制剂进行性别特定研究的需要.
- 结果支持个性化的心律失常管理策略,考虑基于性别的反应.
相关概念视频
01:43Sex-linked Disorders
108.5K
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
108.5K
01:16Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
01:11Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
01:12Trial and Error and Algorithm
399
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
399
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
01:05Difference from Background: Limit of Detection
8.1K
The limit of detection (LOD) is the smallest amount of analyte that can be distinguished from the background noise. The LOD value corresponds to the concentration at which the analyte signal is three times larger than the standard deviation of the blank signal. Below this value, the analyte signal cannot be differentiated from the background noise. It is calculated by dividing the calibration slope by 3 times the standard deviation of the blank signals.
The LOD indicates the presence or absence...
The LOD indicates the presence or absence...
8.1K